Lilly's ramu' has squamous, non-squamous potential

Share this article:
Eli Lilly
Eli Lilly

Eli Lilly's Phase III results for its pipeline oncology drug ramucirumab show the company may open up financial and treatment possibilities among non-small cell lung cancer (NSCLC) patients.

The test included second-line squamous and non-squamous NSCLC patients who were treated with either ramucirumab and docetaxel, or placebo and docetaxel. The company said in a statement that there was “statistically significant improvement in the primary endpoint for overall survival” in the plus-ramucirumab group vs. placebo, as well as a “statistically significant improvement” in progression-free survival in the plus-ramucirumab vs. the chemotherapy-only groups.

This is good news in terms of endpoints, but analysts are divided about what this means in terms of potential market share. The key is Roche's Avastin, which is currently approved for first-line non-squamous NSCLC.

ISI Group analyst Mark Schoenebaum noted in his Wednesday reaction that Roche estimates its share of the US non-squamous NSCLC market is 35% to 40% and that Lilly pegs it at around 20%. Schoenebaum says a non-squamous approval puts Lilly's potential at around $750 million.

Bernstein's Tim Anderson is more optimistic about Lilly's opportunity in the non-squamous market. His reason, as noted in his February 19 analysis, is that “most patients with NSCLC fail whatever first-line therapy they may be receiving,” and the analyst sees a potential $1-billion windfall in this one-treatment scenario.

The squamous setting is a significant opportunity, and both analysts note that Lilly left out some critical information in Wednesday's release, such as what the overall- and progression-free survival came down to in terms of time as well as how many of the Phase-III REVEL patients were non-squamous and how many were squamous.

Schoenebaum described the squamous market as “wide open” with the potential to hit $1 billion. The key is again Avastin, which he notes cannot be prescribed for squamous patients “because of severe bleeding in the lungs.”

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...